Lab
Ihc Health Services, INC.
Ihc Health Services, INC. was paid $17.86M by Medicaid between Jan 2018 and Nov 2024, across 219 billing codes. Its largest line is 87635, Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe — 30% of everything it billed.
33Billing provider infoIHC HEALTH SERVICES, INC.
MURRAY, UT 84107
MURRAY, UT 84107
33aNPI1720029960assigned 06/09/2006
33bProvider typeClinical Medical Laboratory
28Total paid$17.86M
24GClaims1,151,104
24DCodes billed219
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Utah
Rank by total paid#4 of 35
Median peer was paid$385K
This provider vs. median46×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 92,855 | $1.24M | |
| 2019 | 115,280 | $1.35M | |
| 2020 | 186,094 | $3.54M | |
| 2021 | 265,252 | $5.58M | |
| 2022 | 226,434 | $3.59M | |
| 2023 | 159,538 | $1.67M | |
| 2024incomplete | 105,651 | $898K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 30% | 110,298 | 93,183 | $5.42M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 12% | 28,066 | 22,640 | $2.08M |
| 36415 | Collection of venous blood by venipuncture | 7.0% | 98,242 | 83,911 | $1.26M |
| 80050 | General health panel | 4.4% | 16,956 | 15,923 | $779K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 3.7% | 26,663 | 23,939 | $668K |
| 80053 | Comprehensive metabolic panel | 3.0% | 57,371 | 48,058 | $532K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 2.7% | 19,602 | 18,391 | $481K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 2.5% | 10,958 | 10,286 | $445K |
| 80081 | 2.4% | 6,223 | 5,766 | $423K | |
| 80061 | Lipid panel | 2.1% | 36,054 | 33,183 | $379K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 2.1% | 44,440 | 39,989 | $370K |
| 87480 | 1.8% | 7,657 | 6,970 | $318K |
207 more codes
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.7% | 2,891 | $301K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.6% | 31,510 | $292K |
| 87902 | 1.1% | 1,123 | $201K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 54,490 | $157K |
| 87186 | <1% | 18,050 | $134K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 17,911 | $127K |
| 87070 | <1% | 8,862 | $123K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 11,771 | $120K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 26,309 | $119K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,294 | $117K |
| 80074 | <1% | 2,024 | $114K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 14,447 | $101K |
| 87077 | <1% | 13,039 | $100K | |
| 87522 | Neg quan hep c or qual rna | <1% | 3,865 | $99K |
| 87081 | <1% | 28,036 | $99K | |
| 84403 | <1% | 4,530 | $96K | |
| 82607 | <1% | 16,066 | $95K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 795 | $95K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 31,154 | $89K |
| 82728 | <1% | 10,150 | $87K | |
| 86803 | <1% | 9,935 | $84K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 2,453 | $82K |
| 83516 | <1% | 2,979 | $72K | |
| 82670 | <1% | 1,990 | $66K | |
| 86480 | <1% | 1,234 | $59K | |
| 84439 | <1% | 14,490 | $55K | |
| 85027 | <1% | 15,170 | $54K | |
| 83880 | <1% | 1,949 | $54K | |
| 87507 | <1% | 296 | $52K | |
| 84146 | <1% | 2,855 | $45K | |
| 83970 | <1% | 2,381 | $43K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 53,231 | $42K |
| 81001 | <1% | 10,073 | $42K | |
| 87075 | <1% | 1,919 | $41K | |
| 84153 | <1% | 2,432 | $39K | |
| 86592 | <1% | 1,751 | $37K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 659 | $36K |
| 86003 | <1% | 3,128 | $36K | |
| 80076 | <1% | 4,426 | $33K | |
| 87088 | <1% | 11,031 | $33K | |
| 87529 | <1% | 813 | $30K | |
| 82043 | <1% | 10,091 | $29K | |
| 87340 | <1% | 5,580 | $26K | |
| 86140 | <1% | 13,910 | $26K | |
| 82274 | <1% | 1,944 | $26K | |
| 83520 | <1% | 734 | $25K | |
| 84702 | <1% | 4,679 | $25K | |
| 84144 | <1% | 1,790 | $25K | |
| 86704 | <1% | 3,002 | $24K | |
| 84481 | <1% | 4,260 | $24K | |
| 80159 | <1% | 1,527 | $24K | |
| 87510 | <1% | 7,664 | $24K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 828 | $23K |
| 84402 | <1% | 1,086 | $21K | |
| 87660 | <1% | 7,653 | $21K | |
| 86706 | <1% | 3,824 | $21K | |
| 83001 | <1% | 2,497 | $20K | |
| 86376 | <1% | 1,870 | $18K | |
| 84466 | <1% | 7,623 | $18K | |
| 80069 | <1% | 2,897 | $17K | |
| 82784 | <1% | 3,855 | $17K | |
| 86038 | <1% | 2,806 | $17K | |
| 82570 | <1% | 12,617 | $17K | |
| 86235 | <1% | 968 | $17K | |
| 85610 | <1% | 5,978 | $16K | |
| 86200 | <1% | 1,354 | $16K | |
| 83735 | <1% | 7,427 | $15K | |
| 83540 | <1% | 8,699 | $15K | |
| 86850 | <1% | 1,322 | $15K | |
| 80197 | <1% | 1,088 | $15K | |
| 82950 | <1% | 6,751 | $15K | |
| 85652 | <1% | 12,721 | $14K | |
| 86780 | <1% | 4,547 | $14K | |
| 82746 | <1% | 2,785 | $13K | |
| 81479 | Unlisted molecular pathology procedure | <1% | 302 | $13K |
| 80164 | <1% | 1,674 | $13K | |
| 87505 | <1% | 107 | $12K | |
| 80202 | <1% | 1,015 | $12K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 465 | $11K |
| 82105 | <1% | 624 | $11K | |
| 83690 | <1% | 4,405 | $11K | |
| 86769 | <1% | 306 | $10K | |
| 86665 | <1% | 1,969 | $10K | |
| 84270 | <1% | 1,815 | $10K | |
| 86160 | <1% | 1,022 | $10K | |
| 85651 | <1% | 1,739 | $9K | |
| 87324 | <1% | 627 | $9K | |
| 82247 | <1% | 2,221 | $8K | |
| 87147 | <1% | 3,493 | $8K | |
| 80178 | <1% | 1,432 | $7K | |
| 83655 | <1% | 964 | $7K | |
| 36416 | <1% | 1,344 | $7K | |
| 83002 | <1% | 1,283 | $7K | |
| 87338 | <1% | 444 | $7K | |
| 84425 | <1% | 318 | $7K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 253 | $7K |
| 0064U | <1% | 98 | $7K | |
| 86800 | <1% | 1,540 | $6K | |
| 82550 | <1% | 2,269 | $6K | |
| 82525 | <1% | 912 | $5K | |
| 85379 | <1% | 530 | $5K | |
| 86039 | <1% | 423 | $5K | |
| 81003 | <1% | 1,473 | $5K | |
| 86431 | <1% | 2,279 | $5K | |
| 84550 | <1% | 2,038 | $5K | |
| 86787 | <1% | 862 | $4K | |
| 84156 | <1% | 2,773 | $4K | |
| 82533 | <1% | 478 | $4K | |
| 84100 | <1% | 2,752 | $4K | |
| 86790 | <1% | 918 | $4K | |
| 87045 | <1% | 513 | $4K | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 1,064 | $4K |
| 83721 | <1% | 1,406 | $4K | |
| 86225 | <1% | 350 | $3K | |
| 85007 | <1% | 2,961 | $3K | |
| 86663 | <1% | 452 | $3K | |
| 82627 | <1% | 319 | $3K | |
| 86364 | <1% | 1,191 | $3K | |
| 82248 | <1% | 2,093 | $2K | |
| 84480 | <1% | 1,086 | $2K | |
| 80377 | <1% | 458 | $2K | |
| 83993 | <1% | 175 | $2K | |
| 87449 | <1% | 954 | $2K | |
| 84703 | <1% | 463 | $2K | |
| 82951 | <1% | 238 | $2K | |
| 0100U | <1% | 46 | $2K | |
| 86708 | <1% | 119 | $2K | |
| 87631 | <1% | 39 | $2K | |
| 84630 | <1% | 855 | $1K | |
| 84460 | <1% | 903 | $1K | |
| 84165 | <1% | 123 | $1K | |
| 85730 | <1% | 792 | $1K | |
| 0065U | <1% | 158 | $1K | |
| 82785 | <1% | 137 | $1K | |
| 82310 | <1% | 314 | $1K | |
| 81015 | <1% | 343 | $1K | |
| 82947 | <1% | 1,121 | $1K | |
| 82977 | <1% | 989 | $974.80 | |
| 84445 | <1% | 13 | $937.75 | |
| 84145 | <1% | 21 | $866.12 | |
| 83013 | <1% | 15 | $850.46 | |
| 83921 | <1% | 45 | $806.45 | |
| 85014 | <1% | 957 | $795.83 | |
| 82140 | <1% | 67 | $785.91 | |
| 81514 | <1% | 2,098 | $784.23 | |
| 82390 | <1% | 354 | $722.25 | |
| 83525 | <1% | 101 | $706.93 | |
| 86664 | <1% | 438 | $696.65 | |
| 87040 | <1% | 84 | $684.90 | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 240 | $594.20 |
| 87046 | <1% | 533 | $557.43 | |
| 81511 | <1% | 537 | $530.77 | |
| 85018 | <1% | 673 | $529.31 | |
| 80055 | <1% | 29 | $513.56 | |
| 82565 | <1% | 162 | $460.74 | |
| 83615 | <1% | 213 | $456.25 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 99 | $451.57 |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | <1% | 3,860 | $443.08 |
| 84450 | <1% | 238 | $437.69 | |
| 87102 | <1% | 86 | $423.89 | |
| 83088 | <1% | 97 | $418.67 | |
| 82150 | <1% | 304 | $396.93 | |
| 86341 | <1% | 25 | $378.93 | |
| 80175 | <1% | 55 | $370.13 | |
| 87329 | <1% | 86 | $350.24 | |
| 84478 | <1% | 41 | $252.00 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 26 | $251.49 |
| 80177 | <1% | 15 | $251.20 | |
| 83498 | <1% | 12 | $222.78 | |
| 86256 | <1% | 12 | $217.36 | |
| 87076 | <1% | 44 | $216.34 | |
| 81225 | <1% | 74 | $199.47 | |
| 82652 | <1% | 15 | $194.10 | |
| 88142 | <1% | 33 | $190.35 | |
| 87328 | <1% | 12 | $133.96 | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | <1% | 2,170 | $126.49 |
| 86901 | <1% | 65 | $126.11 | |
| 84134 | <1% | 44 | $113.17 | |
| 86141 | <1% | 40 | $103.17 | |
| 82610 | <1% | 14 | $100.01 | |
| 86900 | <1% | 79 | $62.22 | |
| 81241 | <1% | 175 | $59.48 | |
| 84132 | <1% | 12 | $55.68 | |
| 84484 | <1% | 48 | $52.59 | |
| 86258 | <1% | 31 | $44.80 | |
| 82239 | <1% | 14 | $39.82 | |
| 82952 | <1% | 265 | $38.25 | |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | <1% | 137 | $36.03 |
| G0471 | Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha) | <1% | 2,108 | $32.59 |
| 86361 | <1% | 30 | $29.60 | |
| 81025 | <1% | 14 | $24.22 | |
| 85045 | <1% | 62 | $22.68 | |
| 81291 | <1% | 90 | $20.04 | |
| 81231 | <1% | 74 | $17.90 | |
| 84436 | <1% | 13 | $7.27 | |
| 85046 | <1% | 13 | $6.07 | |
| 81328 | 0% | 73 | $0.00 | |
| 81355 | 0% | 73 | $0.00 | |
| 86336 | 0% | 73 | $0.00 | |
| 80361 | 0% | 14 | $0.00 | |
| 84520 | 0% | 14 | $0.00 | |
| 81230 | 0% | 75 | $0.00 | |
| 81240 | 0% | 87 | $0.00 | |
| 81226 | 0% | 74 | $0.00 | |
| 82677 | 0% | 70 | $0.00 | |
| 80349 | 0% | 15 | $0.00 | |
| 81227 | 0% | 76 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLARSEN, DAVE (CFO)
| Provider | Location | Paid |
|---|---|---|
| Ihc Health Services, INC. | Murray, UT | $946K |
| Ihc Health Services, INC. | Tooele, UT | $12K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.